GXG-3 is under clinical development by Ilkogen Ilac San Ve Tic and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect GXG-3’s likelihood of approval (LoA) and phase transition for Chemotherapy Induced Neutropenia took place on 20 Dec 2020, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their GXG-3 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

GXG-3 overview

GX-G3 (G-CSF-hyFc) is under development for the treatment of chemotherapy-induced neutropenia and neutropenia. GXG-3 is a biobetter of G-CSF. It is administered through subcutaneous route in the form of a solution. It is a long-acting version of G-CSF with eliminate anti-body mediated (ADCC) or complementary dependent (CDC) cytotoxic responses. GX-G3 is developed based on hybrid-Fc (hyFc) technology.

Quick View GXG-3 LOA Data

Report Segments
  • Innovator
Drug Name
  • GXG-3
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Hematological Disorders
  • Toxicology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.